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Abstract - Alzheimer’s disease (AD), as the most common form of dementia, has for many years attracted the attention of 
researchers around the world, primarily because of the problems of reliable diagnostic methods that could help in the early 
detection of this devastating disease. One of the important aspects of genetic research related to AD is the analysis of chro-
mosome instability which includes: aneuploidies of different chromosomes, telomere shortening and the phenomenon of 
premature centromere division (PCD). The aim of this study was to describe specific biomarkers in different types of cells 
as potential parameters for the diagnosis of AD in order to promptly recognize pre-symptomatic stages and prevent the 
development of disease and/or slow down its progression.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common form 
of dementia. It is a set of irreversible, neurodegenera-
tive alterations leading to a progressive loss of mem-
ory and intellectual abilities. In AD we can differ-
entiate two basic forms of the disease: sporadic and 
familial (hereditary). Over 90% of all cases of AD 
have the sporadic form that occurs after the 65th year 
of age. Only 5-10% of patients have a familial form 
of AD that is characterized by a much earlier onset 
between 40-50 years of age. The inherited form of the 
disease with early symptoms is caused by autosomal 
dominant mutations in the genes for the synthesis of 
amyloid precursor protein (APP) on chromosome 
21, presenilin 1 on chromosome 14 and presenilin 
2 on chromosome 1 (St. George et al., 1987; Schel-
lenberg et al., 1992; Cruts et al., 1996). 
AD pathology is associated with the loss of neu-
rons and synapses in the cerebral cortex and specific 
subcortical brain regions. Histological indicators of 
these  changes  are  amyloid  plaques  resulting  from 
the accumulation of extracellular fibrils composed 
of  amyloid  beta  protein,  and  neurofibrilar  tangles 
formed from tau protein (Hardy and Selkoe, 2002). 
One of the biggest problems associated with AD is 
the lack of reliable diagnostic methods to confirm 
AD during the life of the patient and also the lack 
of methods by which we could highlight some of the 
presymptomatic states in these patients which could 
consequently reduce the risk of developing AD. 
In the numerous scientific studies related to AD 
there are different directions of research. The largest 
volume of research is related to the peptide amyloid 
beta (A-beta) and tau protein. Also, considerable re-
search is directed towards studies of genetic changes 
that are directly related to the disease. In this paper 
the focus will be on chromosome instability in AD 
with special emphasis on: (1) the significance of ane-
uploidy in the process of neurodegeneration in AD, 604 B. SPREMO-POTPAREVIĆ  ET AL.
(2) the importance of telomere shortening, and (3) 
the phenomenon of premature centromere division 
(PCD) of individual chromosomes in patients with 
AD. Tests for chromosomal instability in AD, as well 
as many other studies, are aimed at finding specific 
biomarkers  that  could  present  possible  diagnostic 
parameters of AD in order to influence neurodegen-
erative processes by slowing down the progress of the 
disease in these patients.
Aneuploidy in Alzheimer’s disease
An adult human body is made at least of 1014 cells 
and 210 different types of cell. They all originate 
from the first diploid cell (zygote); the end-result 
is 1016 mitotic divisions which is about 45 cell gen-
erations (Iourov et al., 2010). It is hard to imagine 
that all these cells share the same genome. Genomic 
variations in somatic cells are constantly present as 
a consequence of 104-105 DNA lesions per day. Most 
of the lesions are corrected by repair mechanisms, 
but at the same time these processes represent one 
of the exogenous sources of change in the human 
genome and may be a cause of different pathologi-
cal processes (Jackson and Bartek, 2009). During 
the numerous cell divisions in an organism, aneu-
ploidy, i.e., changes in the chromosome number, oc-
curs very often. Chromosome instability, including 
aneuploidy, is considered as one of the mechanisms 
of aging at the cellular level (Yurov et al., 2009; Fin-
kel et al., 2007). On the other hand, numerous au-
thors point to the fact that aneuploidy is a relevant 
factor in neurodegenerative changes in AD (Potter, 
1991; Potter, 2010; Kormann-Bortolotto et al., 1993; 
Migliore et al., 1997; Žekanovski and Wojda, 2009). 
Early studies have shown that the median frequen-
cy of aneuploidy in the neurons of healthy adults 
is about 10%, which corresponds to a frequency of 
0.1-0.7% per chromosome pair (Iourov et al., 2006). 
In a fetal brain this frequency is 2-3 times higher 
and probably is a consequence of numerous mi-
totic divisions, while apoptosis is the mechanism 
by which the organism eradicates aneuploid cells 
(Yurov et al., 2007). Also, it has been shown that 
aneuploid neurons in healthy adults are function-
ally active due to changes in genomic expression 
when compared to euploid neurons (Kingsbury et 
al., 2005). In the brains of AD subjects the number 
of aneuploid neurons exceeds 20% (Mosch, 2007). 
However, in the pyramidal neurons of the hippoc-
ampus of AD patients aneuploidy is present in 3-4% 
of cells (Yang et al., 2001). 
Increased aneuploidy of chromosome 17 and 21 
was also shown at the periphery, in cells of the buc-
cal epithelium of AD patients (Thomas and Fenech, 
2008). At the same time, Iourov et al. (2008) has ap-
plied  a  new  molecular  cytogenetic  technique  and 
analyzed interphase chromosomes by a specific mul-
ticolor banding (ICS-MCB) in order to evaluate the 
aneuploidy of chromosome 21 in different parts of 
the brains of AD patients and corresponding con-
trols. In all investigated parts of the brain, i.e. the 
cerebral cortex, hippocampus and cerebellum, the 
percentage of aneuploidy of chromosome 21 in AD 
was significantly higher than in controls. In the con-
trol samples the average frequency of aneuploidy of 
chromosome 21 was 0.7%, but in the samples of AD 
brains the aneuploidy of chromosome 21 was present 
in over 20% of cells (Iourov et al., 2008).
The relationship between Down’s syndrome (DS) 
and AD was described two decades ago by Potter et 
al. (1991). In DS patients around the age of 30 rapid 
changes to the brain occur, which histologically can-
not be distinguished from those found in AD patients 
(Wisniewski et al., 1988; Petronis, 1999; Stanton and 
Coetzee, 2004; Granic et al., 2010). Since it is known 
that the gene for APP is located on chromosome 21 
on the position q21, it is considered that chromo-
some 21 trisomy can lead to an increased synthesis 
of this protein and accordingly to increased produc-
tion of the beta amyloid peptide that is responsible 
for pathological changes in the brain (Oyama et al., 
1994; Petterson and Costa, 2005). The consequence 
of chromosome segregation disturbance is found to 
affect chromosome 21 resulting in its trisomy (Pot-
ter,  2008).  There  is  more  and  more  evidence  that 
AD is characterized by alterations of the cell cycle in 
post-mitotic neurons, which consequently result in 
genomic variability primarily represented by aneu-
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Telomere shortening in Alzheimer’s disease
Telomeres are repetitive, non-coding sequences of 
DNA located on the ends of chromosomes. Telom-
eres shorten after each cell division due to the incom-
plete synthesis of the lagging strand of DNA, per rep-
lication process. The shortest telomeres are found in 
cells that are mitotically very active, such as skin and 
gastrointestinal epithelial cells and white blood cells. 
In human newborn cells, telomere length is about 
15-20 kb and it is gradually reduced over a lifetime. 
So we can say that telomere length represents a bio-
logical counter for the number of cell divisions, re-
flecting the replicative history of each cell (Shay and 
Wright, 2007).
Unlike most somatic cells, the constant telomere 
length in stem cells, male gametes and cancer cells is 
maintained by the presence of the enzyme telomer-
ase. Telomerase is composed of two essential com-
ponents: a catalytic subunit with a function of a re-
verse transcriptase (TERT) (Nakamura et al., 1997) 
and an RNA telomerase subunit (Feng et al., 1995). 
The mechanism of telomerase action is in the add-
ing of TTAGGG repetitive sequence at the ends of 
chromosomes which compensates for the erosion of 
telomeres which happens in its absence (Blackburn 
1992; Greider et al., 1985; Cristofaro and Lingner, 
2006). Most human differentiated cells do not ex-
press telomerase This causes the cell to lose a part 
of the telomere at each division. The consequences 
of these kinds of processes in cells can be termed 
as  replicative  aging.  Therefore,  one  of  the  many 
theories of aging is based on telomere shortening. 
Panossian  et  al.  (2003)  analyzed  telomere  length 
in the cells of the immune system in AD patients 
and showed that the telomeres of T lymphocytes in 
AD patients are shorter than in the corresponding 
control group. Lukens et al. (2009) made a study 
measuring  telomere  length  in  peripheral  blood 
leukocytes (PBL) in AD patients and in an appro-
priately age-matched control. They also questioned 
the length of telomeres in cerebellar neurons. The 
results of this study revealed that the telomeres of 
the PBL in AD patients were significantly shorter 
than in the corresponding controls, but the differ-
ences in telomere length in the cerebellar neurons 
of AD patients and controls were not statistically 
significant. It is not clear whether the latter result 
reflects the status of telomeres in the nerve cells of 
other brain areas, but the authors believe that the 
telomere length may be a marker of changes in dif-
ferent tissues of AD patients.
The Nobel Prize for medicine and physiology 
in 2009 was awarded to two researchers from the 
U.S., Carol Greider and Jank Szostak, and a scientist 
from Australia, Elizabeth Blackburn, for the discov-
ery of the role of telomere shortening and its impli-
cations in the aging process and cancer. As for the 
activity of telomerase, aging cells and its malignant 
transformation are two sides of the same coin. Inhi-
bition of telomerase in cancerous cells could be an 
end-point for researchers in cancer biology, while 
the expression of telomerase in normal cells would 
mean an extension of a healthy life expectancy. This 
view could have significance for diseases related to 
aging processes, such as the sporadic form of AD. 
Study of the gene for the enzyme telomerase will 
have several important applications in future medi-
cal research and cell engineering (Shay and Wright, 
2007).
Premature centromere division (PCD) and  
Alzheimer’s disease
Centromeres in chromosomes are the regions that 
hold the sister chromatids together during the period 
from completion of replication to early anaphase of 
mitosis and the first meiotic division. Centromeres 
have a fundamental role in the proper segregation of 
chromosomes during cell division, establishing the 
connection with microtubules of the mitotic spindle 
and  in  chromosome  movement  toward  the  poles. 
PCD can be defined as a phenomenon of an earlier 
than usual centromere separation of chromosomes. 
This phenomenon was first described in the met-
aphase X chromosome in healthy, older women (Fit-
zgerald and McEwan, 1977). Later it was shown that 
there is a correlation between the presence of PCD 
and X chromosome aneuploidy (Nakagome et al., 
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In the PBL of AD patients there is a higher 
percentage  of  PCD  on  chromosomes  than  in 
control groups (Migliore et al., 1997), which is 
especially true for the X chromosome (Spremo-
Potparević  et  al.,  2004)  and  chromosome  18 
(Živković et al. 2006). Using the method of fluo-
rescent in situ hybridization (FISH) for centro-
mere  regions  of  the  these  chromosomes  it  was 
shown that in sporadic AD patients PCD already 
occurs in the interphase of the cell cycle, imme-
diately after the replication process in the PBL 
(Spremo-Potparević et al., 2004, Živković et al., 
2006). These authors pointed out an increase in 
the level of hyperploidy and hipoploidy in AD 
patients, which may be a consequence of chro-
mosome instability and PCD on the interphase 
chromosomes. In the interphase neurons of the 
cerebral cortex of sporadic AD patients, the pres-
ence  of  PCD  X  chromosome  was  corroborated 
by the FISH method (Spremo-Potparević et al., 
2008).  All  the  aforementioned  findings  could 
point to the loss of spatial and temporal control 
of centromere separation and segregation, which 
results  in  impaired  microtubule  organization 
and errors in the sister chromatid segregation of 
chromosomes. Cyclin dependent kinase 11 (CDK 
11) may have an important role in these process-
es, particularly in the progression of mitosis and 
maintenance of sister chromatid cohesion (Bajic 
et al., 2008; 2011). The presence of PCD in the 
interphase  chromosomes  of  the  cerebral  cortex 
neurons of AD patients is proof that these cells 
perform DNA replication and confirms that neu-
rons in AD actually enter into a new cell cycle, 
because only replicated chromosomes can exhibit 
the phenomenon of PCD. It was also shown that 
postmitotic neurons do not have the ability to di-
vide (Currais et al., 2009).
PCD in neurons can be considered as evidence 
of the deregulation of the cell cycle that leads to 
neurodegeneration and eventually to cell death. It 
is likely that the described events are one of the im-
portant mechanisms of the rapid neurodegenerative 
process in the brains of patients with AD.
CONCLUSIONS
In patients affected by AD the presence of chromo-
some instability has been established in both cells of 
the central nervous system and different cell types in 
the periphery. Chromosome instability is reflected 
by the presence of numerous but specific changes. 
Aneuploidy of different chromosomes is present in 
peripheral blood cells a few years before the onset of 
the clinical symptoms of AD. Telomeres are signifi-
cantly shorter in the PBL of AD patients compared to 
controls. The presence of the phenomenon of PCD in 
the cells of AD patients leads to a loss of hierarchy in 
the process of separation and segregation of chromo-
somes that is spatially and temporally determined. 
These facts can be crucial to finding specific biomar-
kers that will contribute to the timely and precise di-
agnosis of Alzheimer’s disease.
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